Dopaminergic agonists such as bromocriptine suppress insulin and leptin release by reducing peak amplitude of their rhythmic release, and have been associated with improved metabolic function in obese subjects with metabolic syndrome, and subjects suffering from T2D (29, 30). This evidence concerns the gene INS and metabolic syndrome.